{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:32:22Z","timestamp":1789558342584,"version":"build-2803163510"},"reference-count":47,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.xcrm.2026.102789","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T14:41:46Z","timestamp":1778078506000},"page":"102789","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1\/2 trial results"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4543-5553","authenticated-orcid":false,"given":"David A.","family":"Braun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus S.","family":"Noel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan H.","family":"Moy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Demel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arif","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirish","family":"Gadgeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Peguero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Emamekhoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Van Tine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rama","family":"Balaraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GiNell","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sritama","family":"Nath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott R.","family":"Daigle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavan","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Scheuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sommerhalder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.102789_bib1","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102789_bib2","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2026.102789_bib3","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41392-022-01136-2","article-title":"Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.xcrm.2026.102789_bib4","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.ccell.2025.03.006","article-title":"Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy","volume":"43","author":"Wang","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.102789_bib5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.xcrm.2026.102789_bib6","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1001\/jamaoncol.2019.2187","article-title":"Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non\u2013small cell lung cancer treated with nivolumab","volume":"5","author":"Topalian","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.xcrm.2026.102789_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00114","article-title":"Comparative analysis of durable responses on immune checkpoint inhibitors versus other systemic therapies: a pooled analysis of phase III trials","volume":"3","author":"Pons-Tostivint","year":"2019","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.xcrm.2026.102789_bib8","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102789_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006533","article-title":"Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies","volume":"11","author":"Anderson","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2026.102789_bib10","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102789_bib11","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102789_bib12","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102789_bib13","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102789_bib14","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1158\/2326-6066.CIR-20-0586","article-title":"Hallmarks of resistance to immune-checkpoint inhibitors","volume":"10","author":"Karasarides","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.xcrm.2026.102789_bib15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.xcrm.2026.102789_bib16","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102789_bib17","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1038\/s41467-023-40745-5","article-title":"Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype","volume":"14","author":"Hiltbrunner","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102789_bib18","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"184","author":"Morad","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102789_bib19","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.55122","article-title":"A perspective on HPK1 as a novel immuno-oncology drug target","volume":"9","author":"Sawasdikosol","year":"2020","journal-title":"eLife"},{"key":"10.1016\/j.xcrm.2026.102789_bib20","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/bs.ai.2015.09.006","article-title":"Map4k family kinases in immunity and inflammation","volume":"129","author":"Chuang","year":"2016","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.xcrm.2026.102789_bib21","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.celrep.2018.09.012","article-title":"The kinase activity of hematopoietic progenitor kinase 1 is essential for the regulation of T cell function","volume":"25","author":"Hernandez","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2026.102789_bib22","article-title":"1367 A highly-selective HPK1 inhibitor enhances T cell receptor signaling and T cell activation potential, increasing antigen recognition and efficacy of PD-1 therapy","volume":"10","author":"Nager","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2026.102789_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114819","article-title":"The development of small-molecule inhibitors targeting HPK1","volume":"244","author":"Zhou","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.xcrm.2026.102789_bib24","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1084\/jem.20062066","article-title":"A novel pathway down-modulating T cell activation involves HPK-1\u2013dependent recruitment of 14-3-3 proteins on SLP-76","volume":"204","author":"Di Bartolo","year":"2007","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.xcrm.2026.102789_bib25","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1083\/jcb.201103105","article-title":"Release of serine\/threonine-phosphorylated adaptors from signaling microclusters down-regulates T cell activation","volume":"195","author":"Lasserre","year":"2011","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.xcrm.2026.102789_bib26","doi-asserted-by":"crossref","first-page":"45207","DOI":"10.1074\/jbc.M106811200","article-title":"Hematopoietic progenitor kinase 1 associates physically and functionally with the adaptor proteins B cell linker protein and SLP-76 in lymphocytes","volume":"276","author":"Sauer","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.xcrm.2026.102789_bib27","doi-asserted-by":"crossref","first-page":"11037","DOI":"10.1074\/jbc.M111.310946","article-title":"Down-regulation of B cell receptor signaling by hematopoietic progenitor kinase 1 (HPK1)-mediated phosphorylation and ubiquitination of activated B cell linker protein (BLNK)","volume":"287","author":"Wang","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.xcrm.2026.102789_bib28","doi-asserted-by":"crossref","first-page":"6187","DOI":"10.4049\/jimmunol.0802631","article-title":"Hematopoietic progenitor kinase 1 is a negative regulator of dendritic cell activation","volume":"182","author":"Alzabin","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.xcrm.2026.102789_bib29","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00262-009-0761-0","article-title":"Hematopoietic progenitor kinase 1 is a critical component of prostaglandin E2-mediated suppression of the anti-tumor immune response","volume":"59","author":"Alzabin","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.xcrm.2026.102789_bib30","article-title":"Critical role of kinase activity of hematopoietic progenitor kinase 1 in anti-tumor immune surveillance","volume":"14","author":"Liu","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2026.102789_bib31","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.08.001","article-title":"Hematopoietic progenitor kinase 1 (HPK1) mediates T cell dysfunction and is a druggable target for T cell-based immunotherapies","volume":"38","author":"Si","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.102789_bib32","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/ni.2121","article-title":"The kinase GLK controls autoimmunity and NF-\u03baB signaling by activating the kinase PKC-\u03b8 in T cells","volume":"12","author":"Chuang","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xcrm.2026.102789_bib33","article-title":"Discovery of NDI-101150, a highly potent and selective HPK1 inhibitor for the treatment of cancer, through structure-based drug design","author":"Kaila","year":"2024","journal-title":"Am. Chem. Soc."},{"key":"10.1016\/j.xcrm.2026.102789_bib34","article-title":"NDI-101150 is a potent and highly selective hematopoietic progenitor kinase 1 (HPK1) inhibitor that promotes a robust and broad anti-tumor immune response","volume":"11","author":"Ciccone","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2026.102789_bib35","article-title":"741 TWT-101: A first-in-clinic study of CFI-402411, a hematopoietic progenitor kinase-1 (HPK1) inhibitor, as single agent or combined with pembrolizumab in subjects with advanced solid malignancies","volume":"11","author":"Papadopoulos","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2026.102789_bib36","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1200\/JCO.2024.42.16_suppl.2585","article-title":"A first-in-human phase 1a dose-escalation study of BGB-15025 (HPK1 inhibitor) as monotherapy and in combination with tislelizumab (TIS; anti-PD-1 antibody) in patients (pts) with advanced solid tumors","volume":"42","author":"Deva","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102789_bib37","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(24)01758-6","article-title":"Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 study","volume":"404","author":"Choueiri","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2026.102789_bib38","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0140-6736(23)00922-4","article-title":"Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial","volume":"402","author":"Pal","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2026.102789_bib39","unstructured":"Merck & Eisai. (2025). Merck and Eisai announce WELIREG (belzutifan) plus LENVIMA (lenvatinib) met primary endpoint of progression-free survival (PFS) in certain previously treated patients with advanced renal cell carcinoma. Press release, October 28, 2025. Available at: https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-and-Eisai-Announce-WELIREG-belzutifan-Plus-LENVIMA-lenvatinib-Met-Primary-Endpoint-of-Progression-Free-Survival-PFS-in-Certain--VLW1Q.pdf."},{"key":"10.1016\/j.xcrm.2026.102789_bib40","unstructured":"Merck. (2025). Merck Announces KEYTRUDA (Pembrolizumab) Plus WELIREG (Belzutifan) Met Primary Endpoint of Disease-free Survival (DFS) in Certain Patients with Clear Cell Renal Cell Carcinoma (RCC) Following Nephrectomy. Press release, October 28, 2025. Available at: https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Announces-KEYTRUDA-pembrolizumab-Plus-WELIREG-belzutifan-Met-Primary-Endpoint-of-Disease-Free-Survival-DFS-in-Certain-Patients--8VRDG.pdf."},{"key":"10.1016\/j.xcrm.2026.102789_bib41","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004235","article-title":"First-in-human phase I\/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors","volume":"10","author":"Davis","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2026.102789_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101184","article-title":"Anti-TIGIT therapies for solid tumors: a systematic review","volume":"8","author":"Rousseau","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.xcrm.2026.102789_bib43","unstructured":"KEYTRUDA (pembrolizumab) prescribing information. (2025). Merck & Co., Inc., Rahway, NJ, USA; revised April 2025. Available at: https:\/\/www.merck.com\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf."},{"key":"10.1016\/j.xcrm.2026.102789_bib44","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2024-4932","article-title":"UltiAnalyzer.AI: an automatic and robust AI-driven tool for the quantification of multiplex immunofluorescence whole slide images","volume":"84","author":"Cardenes","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102789_bib45","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1038\/s41467-019-12464-3","article-title":"Single-cell transcriptomics of human T cells reveals tissue and activation signatures in health and disease","volume":"10","author":"Szabo","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102789_bib46","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13073-019-0655-5","article-title":"Correction to: Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data","volume":"11","author":"Finotello","year":"2019","journal-title":"Genome Med."},{"key":"10.1016\/j.xcrm.2026.102789_bib47","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41467-022-28020-5","article-title":"Advances in mixed cell deconvolution enable quantification of cell types in spatial transcriptomic data","volume":"13","author":"Danaher","year":"2022","journal-title":"Nat. Commun."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126002065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126002065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T01:50:55Z","timestamp":1779414655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126002065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2666379126002065"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102789","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1\/2 trial results","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102789","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102789"}}